Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the earnings per share (EPS) high or low?
The earnings per share (EPS) of -0.99 is 52% above its 5-year average of -2.07, near the high end of its 5-year range (-2.78–-0.99).
28.26% above its 12-month average of -1.38.
Reported quarterly EPS; no daily interpolation. Q2 FY2026 (2026-06-30): -0.10.
EPS growth vs the same fiscal quarter in the prior fiscal year, last 25 comparable quarters.
EARNINGS PER SHARE (EPS)
-0.99
EARNINGS PER SHARE (EPS) AVG TTM
-1.38
EARNINGS PER SHARE (EPS) AVG 3Y
-1.93
EARNINGS PER SHARE (EPS) AVG 5Y
-2.07
EARNINGS PER SHARE (EPS) AVG 10Y
N/A
EARNINGS PER SHARE (EPS) AVG 15Y
N/A
EARNINGS PER SHARE (EPS) AVG 20Y
N/A
CURRENT VS TTM AVG
+28.26%
CURRENT VS 3Y AVG
+48.70%
CURRENT VS 5Y AVG
+52.10%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Foghorn Therapeutics Inc.
Market Cap
$117.43M
Earnings Per Share (EPS)
-0.99
TTM Avg
-1.38
3Y Avg
-1.93
5Y Avg
-2.07
Market Cap
$118.02M
Earnings Per Share (EPS)
-1.08
TTM Avg
-1.62
3Y Avg
-1.56
5Y Avg
-1.43
Market Cap
$116.59M
Earnings Per Share (EPS)
-0.89
TTM Avg
-0.91
3Y Avg
-0.79
5Y Avg
-0.74
Market Cap
$118.63M
Earnings Per Share (EPS)
N/A
TTM Avg
-5.70
3Y Avg
-9.83
5Y Avg
-0.70
Market Cap
$119.09M
Earnings Per Share (EPS)
-0.54
TTM Avg
-0.92
3Y Avg
-84.40
5Y Avg
-674.41
Market Cap
$114.24M
Earnings Per Share (EPS)
-3.21
TTM Avg
-1.79
3Y Avg
-1.14
5Y Avg
-1.14
Market Cap
$113.77M
Earnings Per Share (EPS)
-1.07
TTM Avg
-1.13
3Y Avg
-1.07
5Y Avg
-0.91
Market Cap
$111.17M
Earnings Per Share (EPS)
-0.74
TTM Avg
-0.44
3Y Avg
-1.32
5Y Avg
-1.80
Market Cap
$125.27M
Earnings Per Share (EPS)
-0.28
TTM Avg
-1.88
3Y Avg
-2.46
5Y Avg
-1.80
| NAME | MARKET CAP | EARNINGS PER SHARE (EPS) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Foghorn Therapeutics Inc. (FHTX) | $117.43M | -0.99 | -1.38 | -1.93 | -2.07 |
| Caribou Biosciences, Inc. (CRBU)vs › | $118.02M | -1.08 | -1.62 | -1.56 | -1.43 |
| Genelux Corporation (GNLX)vs › | $116.59M | -0.89 | -0.91 | -0.79 | -0.74 |
| BGM Group Ltd. (BGM)vs › | $118.63M | N/A | -5.70 | -9.83 | -0.70 |
| TuHURA Biosciences, Inc. (HURA)vs › | $119.09M | -0.54 | -0.92 | -84.40 | -674.41 |
| Aardvark Therapeutics, Inc. Common Stock (AARD)vs › | $114.24M | -3.21 | -1.79 | -1.14 | -1.14 |
| Coya Therapeutics, Inc. (COYA)vs › | $113.77M | -1.07 | -1.13 | -1.07 | -0.91 |
| Black Diamond Therapeutics, Inc. (BDTX)vs › | $111.17M | -0.74 | -0.44 | -1.32 | -1.80 |
| enGene Holdings Inc. (ENGN)vs › | $125.27M | -0.28 | -1.88 | -2.46 | -1.80 |
| Apyx Medical Corporation (APYX)vs › | $109.49M | -0.21 | -0.47 | -0.54 | -0.49 |
Trailing EPS (TTM)
$-0.99
Forward EPS (Est.)
$-0.91
P/E Ratio
N/A
Formula: EPS = Net Income / Weighted Average Shares Outstanding
Why EPS matters:
EPS (Earnings Per Share) represents the portion of a company's profit allocated to each outstanding share. Higher EPS indicates greater profitability on a per-share basis.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EARNINGS PER SHARE (EPS) |
|---|---|
| 2025-12-31 | -1.18 |
| 2024-12-31 | -1.58 |
| 2023-12-31 | -2.34 |
| 2022-12-31 | -2.62 |
| 2021-12-31 | -2.78 |
| 2020-12-31 | -1.90 |
| 2019-12-31 | -1.40 |
| 2018-12-31 | -1.34 |
